# Emerging Prognostic and Predictive Biomarkers for Human Cytomegalovirus Infection During Pregnancy: Unmet Needs and Future Perspectives

## TL;DR

This paper reviews the current gaps in biomarkers for managing human cytomegalovirus infection during pregnancy and highlights the need for new tools to improve outcomes for mothers and babies.

## Contribution

The paper identifies unmet needs in HCMV biomarker research and emphasizes priorities for future innovation.

## Key findings

- Current biomarkers for HCMV in pregnancy are insufficient for predicting fetal transmission and damage.
- Novel biomarkers could improve prenatal management and outcomes for congenital HCMV.
- Research priorities include better risk assessment and long-term outcome prediction.

## Abstract

Human cytomegalovirus (HCMV) infection during pregnancy is a leading cause of congenital infections worldwide, posing significant risks to fetal health. Despite advances in prenatal care, managing HCMV infection remains challenging. Early detection, accurate risk assessment, and timely intervention are critical to mitigating the adverse outcomes associated with congenital HCMV (cHCMV), such as neurodevelopmental delays and hearing loss. However, the current landscape of biomarkers for HCMV infection in pregnancy is marked by several unmet needs. These gaps in biomarker development and application limit our ability to predict fetal transmission, assess the risk of fetal damage, and prognosticate long-term outcomes. Addressing these challenges through the identification and validation of novel biomarkers could revolutionize the management of HCMV in pregnancy, leading to improved outcomes for both mothers and their children. This review examines the critical unmet needs regarding HCMV biomarkers during pregnancy, emphasizing the priority areas for further research and innovation.